Antidepressant-like effects of ecstasy in subjects with a predisposition to depression

Addictive Behaviors

Volumn 37, Issue 10, 2012, Pages 1189-1192

  Majumder, Irina ^a,b   White, Jason M ^a   Irvine, Rodney J ^b  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

3,4 Methylenedioxymethamhetamine; Depressive symptoms; Ecstasy; MDMA; Predisposition to depression

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE;

ADULT; ARTICLE; BECK DEPRESSION INVENTORY; BRIEF SYMPTOM INVENTORY; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DISEASE PREDISPOSITION; EXPOSURE; FEMALE; HUMAN; MALE; MOOD DISORDER; PROFILE OF MOOD STATES; SALIVA ANALYSIS; SELF MEDICATION; SOCIALIZATION; SYMPTOM;

AFFECT; CASE-CONTROL STUDIES; DEPRESSIVE DISORDER; FEMALE; HUMANS; MALE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; QUESTIONNAIRES; SEROTONIN AGENTS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84863217174     PISSN: 03064603     EISSN: 18736327     Source Type: Journal    
DOI: 10.1016/j.addbeh.2012.05.022     Document Type: Article

References (19)

1. Alati R., Kinner S.A., Hayatbakhsh M.R., Mamun A.A., Najman J.M., Williams G.M. Pathways to ecstasy use in young adults: Anxiety, depression or behavioural deviance?. Drug and Alcohol Dependence 2008, 92:108-115.
2. Beck A.T., Steer R.A., Brown G.K. Beck Depression Inventory-II. Manual 1996, Psychological Corporation, San Antonio, TX.
3. Cami J., Farre M., Mas M., Roset P.N., Poudevida S., Mas A., et al. Human pharmacology of 3,4-methylenedioxymethamphetamine ("ecstasy"): Psychomotor performance and subjective effects. Journal of Clinical Psychopharmacology 2000, 20:455-466.
4. de Win M.M., Reneman L., Reitsma J.B., den Heeten G.J., Booij J., van den Brink W. Mood disorders and serotonin transporter density in ecstasy users-The influence of long-term abstention, dose, and gender. Psychopharmacology 2004, 173:376-382.
5. de Win M.M., Schilt T., Reneman L., Vervaeke H., Jager G., Dijkink S., et al. Ecstasy use and self-reported depression, impulsivity, and sensation seeking: A prospective cohort study. Journal of Psychopharmacology 2006, 20:226-235.
6. Derogatis L.R., Melisaratos N. The Brief Symptom Inventory: An introductory report. Psychological Medicine 1983, 13:595-605.
7. Falck R.S., Jichuan W., Carlson R.G. Depressive symptomatology in young adults with a history of MDMA use: A longitudinal analysis. Journal of Psychopharmacology 2008, 22:47-54.
8. Green A.R., Mechan A.O., Elliott J.M., O'Shea E., Colado M.I. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacological Reviews 2003, 55:463-508.
9. Hall D.H., Queener J.E. Self-medication hypothesis of substance use: Testing Khantzian's updated theory. Journal of Psychoactive Drugs 2007, 39:151-158.
10. Huizink A.C., Ferdinand R.F., van der Ende J., Verhulst F.C. Symptoms of anxiety and depression in childhood and use of MDMA: Prospective, population based study. BMJ 2006, 332:825-828.
11. Khantzian E.J. The ego, the self, and opiate addiction: Theoretical and treatment considerations. NIDA Research Monograph 1977, 101-117.
12. Khantzian E.J. The self-medication hypothesis of substance use disorders: A reconsideration and recent applications. Harvard Review of Psychiatry 1997, 4:231-244.
13. Lieb R., Schuetz C.G., Pfister H., von Sydow K., Wittchen H. Mental disorders in ecstasy users: A prospective-longitudinal investigation. Drug and Alcohol Dependence 2002, 68:195-207.
14. Majumder I., White J.M., Irvine R.J. Antidepressant-like effects of 3,4-methylenedioxymethamphetamine in an animal model of depression. Behavioural Pharmacology 2011, 22:758-765.
15. McNair D., Lorr M., Droppleman L. The Profile of Mood States 1992, Educational and Industrial Testing Service, San Diego, CA.
16. Peroutka S.J., Newman H., Harris H. Subjective effects of 3,4-methylenedioxymethamphetamine in recreational users. Neuropsychopharmacology 1988, 1:273-277.
17. Roiser J.P., Sahakian B.J. Relationship between ecstasy use and depression: A study controlling for poly-drug use. Psychopharmacology 2004, 173:411-417.
18. Soar K., Turner J.J., Parrott A.C. Problematic versus non-problematic ecstasy/MDMA use: The influence of drug usage patterns and pre-existing psychiatric factors. Journal of Psychopharmacology 2006, 20:417-424.
19. Tancer M., Johanson C.E. The effects of fluoxetine on the subjective and physiological effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology 2007, 189:565-573.